BRD2 and pachyonychia congenita: Future work includes evaluation of BRD2 or BRD4 as a marker of sensitivity to JQ1 + IR and comparison of a BET inhibitor ± IR in low vs high level BRD2 or BRD4 expressing preclinical models of PC.